Analysis for ECL
- 📈 Growth — 12/30
- 💰 Profitability — 14/20
- 🏦 Financial Health — 17/20
- 💵 Valuation — 14/20
- ⚠️ Risk — 5/10
Summary:
📈 Growth & Financial Trajectory
The 8-quarter sequence shows moderate upside but notable volatility. Revenues rose from approximately $3.99B in 2024-Q2 to about $4.07B in 2026-Q1, a net gain of around 2%. Net income peaked around $0.74B in 2024-Q3 and ended 2026-Q1 at about $0.44B, highlighting earnings volatility despite a still-healthy top line.
💰 Margins & Cash Flow
Gross margin stayed in the mid‑40% range (gross profit around $1.65–$1.87B on roughly $4.0B revenue). Operating margin tracked in the teens (roughly 14–17%). Net cash flow from operating activities was generally positive, with occasional pressure from investing/financing; 2026-Q1 shows negative overall cash flow driven by investing activity totalling about -$126M.
🛡️ Balance Sheet & Liquidity
Assets around $22–$24B, liabilities around $13–$15B, and equity near $8.8–$9.9B. Current ratio hovered around 1.0–1.7, indicating modest but durable liquidity.
⚠️ Key Drivers & Risks
- Drivers: broad hygiene and specialty chemical offerings; resilient end-market demand.
- Risks: earnings volatility due to seasonality and mix; sensitivity to input costs and macro cycles; currency effects noted in cash flows.